@article{750a72e4e23541b892744dd3f1e79ff8,
title = "Antiandrogen Treatment vs Active Surveillance for Patients with Prostate Cancer",
author = "Dallin Busby and Mani Menon and Tewari, {Ashutosh K.}",
note = "Funding Information: Conflict of Interest Disclosures: Dr Tewari reported that the authors wish to acknowledge funding support from the Deane Prostate Health, Icahn School of Medicine at Mount Sinai, The Arthur M. Blank Family Foundation, The Kovner Foundation and Lizzie and Jonathan Tisch. Dr Tewari reported serving as a site principal investigator on pharmaceutical/industry-sponsored clinical trials from Kite Pharma Inc, Lumicell, Inc, Dendron Pharmaceuticals, LLC, Oncovir Inc, Blue Earth Diagnostics Ltd, RhoVac ApS, Bayer HealthCare Pharmaceuticals Inc, and Janssen Research and Development, LLC; receiving research funding (grants) to his institution from the Department of Defense, National Institutes of Health, Axogen, Intuitive Surgical, AMBF, and other philanthropy; serving as an unpaid consultant to Roivant Biosciences and adviser to Promaxo; and owning equity in Promaxo. No other disclosures were reported. ",
year = "2023",
month = jan,
day = "19",
doi = "10.1001/jamaoncol.2022.5243",
language = "English",
volume = "9",
pages = "148--149",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "1",
}